Group 1 - Iovance Biotherapeutics Inc. is recognized as a promising immunotherapy stock by hedge funds, with Goldman Sachs raising its price target to $2 from $1.50 while maintaining a Sell rating [1] - The company announced data showcasing a best-in-class profile for its commercial product Amtagvi, demonstrating unprecedented response rates in a real-world clinical study for advanced melanoma patients [2] - Amtagvi is noted as the first one-time T cell therapy for solid tumor cancer and the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and targeted therapy [3] Group 2 - In a study involving 41 evaluable patients with previously treated advanced melanoma, the physician-assessed confirmed objective response rate for Amtagvi was 44%, with a disease control rate of 73% [4] - Iovance Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing tumor-infiltrating lymphocyte (TIL) therapies, with Amtagvi being its lead product candidate [5]

Core Viewpoint - Arcus Biosciences, Inc. (NYSE:RCUS) is experiencing mixed analyst ratings, with recent downgrades and upgrades reflecting uncertainty in its product differentiation and upcoming clinical data readouts [1][2]. Analyst Ratings - Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight, lowering the price target from $30 to $23 due to unclear differentiation for Welireg and potential negative impacts from upcoming data readouts [1]. - Bank of America Securities maintained a Hold rating with a price target of $26 [2]. - Goldman Sachs upgraded the stock from Neutral to Buy, raising the price target from $16 to $28, highlighting the potential of the company's lead asset, casdatifan [2]. Product Development - Casdatifan is a selective HIF-2alpha inhibitor being developed for advanced clear cell renal cell carcinoma, with an estimated total addressable market of approximately 17,400 patients in the US/EU and projected risk-adjusted peak sales of about $1.7 billion [3]. - Phase 1 results for the ARC-20 trial showed overall response rates of 31% for the mono regimen and 46% for the combination regimen, with expectations for further improvement as the trial matures [3]. Company Overview - Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing immunotherapies, competing in the biotechnology and pharmaceutical sectors [4].

Group 1 - Incyte Corporation (NASDAQ:INCY) is recognized as a strong immunotherapy stock by hedge funds, with multiple firms reiterating Buy ratings and raising price targets [1][2][3] - Jefferies set a price target of $120, while Morgan Stanley increased its target to $102 from $94, maintaining an Equal Weight rating [1] - Stifel also raised its price target to $120 from $119, maintaining a Buy rating, while noting a "quiet(ish)" first half but positive long-term outlook [2] Group 2 - Incyte reported Q4 and full-year financial results for 2025, with total revenue of $1.51 billion for the quarter, a 28% increase year-over-year [3] - Full-year revenue reached $5.14 billion, reflecting a 21% growth compared to the previous year, driven by increases in net product revenue and milestone and contract revenue [3] Group 3 - Incyte is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in oncology, hematology, inflammation, and autoimmunity [4]

Core Insights - AstraZeneca PLC (NASDAQ:AZN) is recognized as a promising immunotherapy stock by hedge funds, despite receiving a Sell rating from Deutsche Bank with a price target of £115 [1] Group 1: Clinical Trials and Product Performance - AstraZeneca announced positive results from Phase III KALOS and LOGOS trials for Breztri Aerosphere, demonstrating statistically significant improvements in uncontrolled asthma patients compared to dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines [2] - Breztri also showed clinically meaningful reductions in the annualized rate of severe asthma exacerbations versus ICS/LABA medicines, with no new safety or tolerability concerns identified in the trials [3] Group 2: Company Overview - AstraZeneca is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines, focusing on novel immuno-oncology treatment approaches [4]

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as a leading immunotherapy stock by hedge funds [1] - The company announced a partnership with Life Science Cares to combat food insecurity, aiming to invest $30 million and mobilize 30,000 volunteer hours by 2030 [1] Financial Performance - In fiscal Q4, Bristol-Myers Squibb reported a 1% revenue growth to $12.5 billion, with growth portfolio revenue increasing by 16% to $7.4 billion [3] - Full-year revenues reached $48.2 billion, with growth portfolio revenues rising by 17% to $26.4 billion [3] Analyst Ratings - Bernstein maintained a Hold rating on Bristol-Myers Squibb with a price target of $58.00 [2] - Morgan Stanley raised its price target from $37 to $40 while keeping an Underweight rating, citing that 2026 revenue and EPS guidance exceeded consensus due to a higher-than-expected Eliquis guide [2]

Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansio ...

Core Insights - Merck & Co., Inc. is recognized as a strong immunotherapy investment by hedge funds, with Deutsche Bank upgrading its rating to Buy and increasing the price target to $150 from $115, citing undervaluation due to Keytruda's patent concerns [1] Group 1: Company Developments - On February 11, Merck announced FDA approval for KEYTRUDA® and KEYTRUDA QLEX™ in combination with paclitaxel, for treating adults with PD-L1+ platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma [2] - KEYTRUDA QLEX's effectiveness is supported by well-controlled studies and additional data comparing its pharmacokinetic, efficacy, and safety profiles with KEYTRUDA [3] Group 2: Company Overview - Merck is a biopharmaceutical company focused on health solutions for disease treatment and prevention in both humans and animals, with its Pharmaceutical segment offering vaccines and therapeutic products [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Fa ...

Company Overview - Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, particularly asthma and COPD [3] - The company is headquartered in San Diego, California and is advancing rademikibart, a next-generation antibody targeting IL-4Rα [3] Product Development - Connect Biopharma is conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, which are areas with significant unmet medical needs [3] - The company has granted an exclusive license to Simcere Pharmaceutical Co., Ltd. for rademikibart in Greater China, with potential milestone payments up to approximately $110 million upon achieving certain development, regulatory, and commercial milestones [3] - Connect is also eligible to receive tiered royalties on net sales in Greater China, with rates up to low double-digit percentages [3] Upcoming Events - Company management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 2:40 p.m. ET [1] - A live webcast of the presentation will be available on the company's investor website, with an archived replay accessible for approximately 90 days following the conference [2]

Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing ...